Stephan Hjorth

Integrative Pharmacology, AstraZeneca R&D, Molndal, Sweden 
CNS, appetite, serotonin, cannabinoid, in vivo
"Stephan Hjorth"
Mean distance: 17.32 (cluster 6)
Cross-listing: Chemistry Tree

BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Hjorth S, Waters S, Waters N, et al. (2020) . The Journal of Pharmacology and Experimental Therapeutics
Waters S, Sonesson C, Svensson P, et al. (2020) Preclinical pharmacology of [2-(3-fluoro-5-methanesulfonylphenoxy)ethyl](propyl)amine (IRL790), a novel dopamine transmission modulator for the treatment of motor and psychiatric complications in Parkinson's disease. The Journal of Pharmacology and Experimental Therapeutics
Jansson-Löfmark R, Hjorth S, Gabrielsson J. (2020) Does in vitro potency predict clinical efficacious concentrations? Clinical Pharmacology and Therapeutics
Hjorth S. (2016) Looking back (and in)to the future: A personal reflection on 'Serotonin autoreceptor function and antidepressant drug action' (Hjorth et al., 2000). Journal of Psychopharmacology (Oxford, England)
Walsh SK, Hepburn CY, Keown O, et al. (2015) Pharmacological profiling of the hemodynamic effects of cannabinoid ligands: a combined in vitro and in vivo approach. Pharmacology Research & Perspectives. 3: e00143
Hjorth S, Karlsson C, Jucaite A, et al. (2015) A PET study comparing receptor occupancy by five selective cannabinoid 1 receptor antagonists in non-human primates. Neuropharmacology
Karlsson C, Hjorth S, Karpefors M, et al. (2015) Baseline anandamide levels and body weight impact the weight loss effect of CB1 receptor antagonism in male rats. Endocrinology. 156: 1237-41
Skowronski AA, Morabito MV, Mueller BR, et al. (2014) Effects of a novel MC4R agonist on maintenance of reduced body weight in diet-induced obese mice. Obesity (Silver Spring, Md.). 22: 1287-95
Wennerberg M, Cheng L, Hjorth S, et al. (2011) Binding properties of antagonists to cannabinoid receptors in intact cells. Fundamental & Clinical Pharmacology. 25: 200-10
Boström J, Olsson RI, Tholander J, et al. (2010) Novel thioamide derivatives as neutral CB1 receptor antagonists. Bioorganic & Medicinal Chemistry Letters. 20: 479-82
See more...